GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non-small cell lung cancer (NSCLC)-A randomized, double-blind trial.
JOURNAL OF CLINICAL ONCOLOGY（2022）
关键词
inhibitor gb1211,lung cancer,atezolizumab,double-blind
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要